RADNOR, Pa. / Jul 30, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results.
Tuesday, August 13, 8:30 a.m. E.T.
Domestic: (877) 405-1242
International: (201) 389-0852
Webcast Registration: Click Here
An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/events-and-presentations.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022. For more information about Marinus visit www.marinuspharma.com.
| Last Trade: | US$0.54 |
| Daily Change: | 0.005 0.94 |
| Daily Volume: | 2,441,203 |
| Market Cap: | US$29.650M |
November 12, 2024 October 15, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
